Wall Street analyst estimates for Reviva Pharmaceuticals Holdings, Inc. (RVPH): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.75 |
Valuation Ratios
| Price / Book | 0.00 |
| EV / EBITDA | 7.54 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | $724740 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -$724740 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $946301 | $195744 | $295150 | $4.9M | $18.9M | $31.4M | $22.9M | $11.7M |
| Selling, General & Admin | $175579 | $181116 | $2.1M | $5.3M | $5.4M | $8.1M | $7.9M | $8.5M |
| Operating Expenses | $1.1M | $376860 | $2.4M | $10.1M | $24.3M | $39.5M | $30.8M | $20.2M |
| Operating Income | -$1.1M | -$376860 | -$2.4M | -$10.1M | -$24.3M | -$39.5M | -$30.8M | -$20.2M |
| EBITDA | -$1.1M | -$376014 | -$2.3M | -$10.1M | -$24.1M | -$39.2M | -$29.9M | -$19.8M |
| Interest Expense | $557675 | $469373 | $1.5M | $2414 | $182802 | $33725 | $18497 | $13402 |
| Pre-tax Income | -$1.7M | -$846032 | -$3.8M | -$8.5M | -$24.3M | -$39.2M | -$29.9M | -$19.8M |
| Income Tax | $800 | $800 | $800 | $6004 | $20777 | $16949 | $19514 | $18889 |
| Net Income | -$1.7M | -$846832 | -$3.8M | -$8.5M | -$24.3M | -$39.3M | -$29.9M | -$19.9M |
| EPS | $-16.48 | $-6.20 | $-24.80 | $-11.60 | $-29.00 | $-33.00 | $-18.00 | $-5.48 |
| EPS (Diluted) | $-16.48 | $-6.20 | $-24.80 | $-11.60 | $-29.00 | $-33.00 | $-18.00 | $-5.48 |
| Shares Outstanding (Diluted) | $101984 | $138531 | $153084 | $739542 | $975824 | $1.2M | $1.7M | $3.6M |
Price
| Price | $0.49 |
| Market Cap | $6M |
| Exchange | OTC |
| Country | US |
Related companies: ANVS · ATNM · BCAB · BTAI · CELU · EVAX · FGEN
Explore sector: Healthcare · Biotechnology
More sections of RVPH: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks